Shipment term

Rockley Photonics Announces Delivery of VitalSpex™ Pro Biosensing Technology for Alcohol, Lactate and Glucose Measurement

OXFORD, England & PASADENA, Calif.–(BUSINESS WIRE)–Rockley Photonics Holdings Limited (NYSE: RKLY), a global leader in photonics-based communication and health monitoring solutions, today announced that it has delivered its VitalSpex™ Pro technology for non Invasive Alcohol, Glucose, and Lactate Testing to a Level 1 Early Access Consumer Wearables Client. The shipment of this advanced biomarker detection technology marks a significant milestone in the advancement of next-generation digital healthcare.

“Shipping the improved and more capable Pro version of our VitalSpex biosensing platform is a significant step forward for the future of the digital health category,” said Dr. Andrew Rickman, Chairman and CEO of Rockley. “We believe the ability to continuously monitor a broader range of biomarkers will be a game-changer. Our client’s ability to integrate our biosensing technology into smart wearables has the potential to transform health outcomes by enabling earlier detection of certain conditions and improving the management and treatment of diseases such as hypertension, liver disease or diabetes. With these advances, practitioners like Dr. David Klonoff, Clinical Professor of Medicine at the University of California, San Francisco, increasingly understand that the important insights gained from continuous monitoring of multiple biomarkers provide a holistic view of the health of an individual.

Rockley intends to begin production of the basic version of its VitalSpex biosensing platform, which will measure biomarkers for blood oxygen, blood pressure, body hydration, core body temperature, heart rate, variation in heart rate and respiratory rate, in the second half of 2022. The company plans to begin production of the Pro version of its VitalSpex biosensing platform in 2023, which will measure an expanded range of biomarkers including alcohol, glucose and lactate.

More information about Rockley’s digital health monitoring solution can be found here: https://rockleyphotonics.com/biomarker-sensing

About Rockley Photonics

A world leader in photonics-based health monitoring and communication solutions, Rockley Photonics develops a full range of photonics integrated circuits and associated modules, sensors and complete solutions. From next-generation sensing platforms purpose-built for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications in many sectors. Rockley believes photonics will eventually become as ubiquitous as microelectronics and has developed a platform with the power and flexibility to address both mass markets and a wide variety of vertical applications.

Formed in 2013, Rockley is uniquely positioned to support large scale manufacturing and address a multitude of high volume markets. Rockley has partnered with many Tier 1 customers across a wide range of industries to deliver the complex optical systems needed to bring transformational products to market.

To learn more about Rockley, visit rockleyphotonics.com.

Caution Regarding Forward-Looking Statements

Statements in this press release that are not historical facts constitute “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding expectations, beliefs, plans, objectives and assumptions regarding future events or performance. The words “accelerate”, “move forward”, “anticipate”, “believe”, “may”, “capability”, “continue”, “could”, “develop”, “allow”, “estimate”, “eventually”, “expand”, “expect”, “focus”, “forward”, “future”, “goal”, “intend”, “may”, “could”, “opportunity”, ” perspective”, “plan”, “possible”, “position”, “potential”, “predict”, “project”, “revolution”, “seem”, “should”, “trend”, “vision”, “will” , “would” or other words that predict or indicate future events, trends or expectations, and similar expressions or the negative form of such expressions may identify forward-looking statements, but the absence of such words or terms does not does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, statements regarding the following: (a) the potential of Rockley’s sensing platform to provide real-time information on a variety of health issues and enable early detection of disease states by enabling detection of various biomarkers from a wearable device; (b) the importance of the ability to monitor key biomarkers on an ongoing basis; (c) the ability to provide insight into various chronic diseases such as diabetes and other diseases; (d) Rockley’s ability to support remote health monitoring, improve patient compliance and generally improve the well-being of people around the world; (e) Rockley’s intention to begin production of its base solution in the second half of 2022; (f) Rockley’s plan to begin production of its Pro solution in 2023; (g) the potential impact of the ability to miniaturize monitoring of key biomarkers in a tiny form factor; (h) the ability of Rockley’s detection platform PIC sensors to detect detail beyond today’s LED-based sensor technology; (i) the potential effectiveness of the portable detection platform to monitor biomarkers; (j) the timing and potential results of Rockley’s ongoing human studies and the ability of these studies to help optimize algorithms and fine-tune performance across a broad range of biomarkers; (k) the expectation that the cloud-based analytics and AI capabilities of Rockley’s platform can help develop a more holistic assessment of a person’s health and well-being; (l) Rockley’s belief that its cloud and AI infrastructure can enable additional capabilities for the growing digital health field and help individuals make more informed decisions about their health and well-being; (m) the characteristics, scope, objectives and intended and potential benefits of the Company’s platform, products and technology; (n) its development of a range of photonic integrated circuits and associated modules, sensors and complete solutions; (o) Rockley’s belief that photonics will eventually become as widespread as microelectronics; and (p) Rockley’s potential to support large-scale manufacturing, address a multitude of high-volume markets, and provide the complex optical systems needed to bring transformational products to market.

Forward-looking statements are subject to numerous risks and uncertainties (many of which are beyond Rockley’s control) or other assumptions that could cause actual results or performance to differ materially from those expressed or implied by such statements. forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) Rockley’s ability to achieve customer acceptance and commercial production of its products and technology, including in a timely and cost-effectively; (ii) Rockley’s ability to win customer design contracts and convert memorandums of understanding and development contracts into production contracts; (iii) purchase order risks, including lack of long-term purchase commitments, cancellation, reduction, delay or other changes to customer purchase orders, and if and to the extent customers seek to enter into license agreements instead of purchases; (iv) Rockley’s history of losses and need for additional capital and its ability to access additional financing to support its operations and execute its business plan, and the risks associated therewith; (v) legal and regulatory risks; (vi) the risks associated with its fabless manufacturing model and its reliance on third-party suppliers; (vii) Rockley’s dependence on a few large customers for the majority of its revenues and its ability to expand and diversify its customer base; (viii) Rockley’s financial performance; (ix) the impacts of COVID-19 on Rockley, its customers and suppliers, its target markets and the global economy; (x) Rockley’s ability to successfully manage growth and its operations as a public company; (xi) fluctuations in Rockley’s stock price and Rockley’s ability to maintain the listing of its common stock on the NYSE; (xii) Rockley’s ability to anticipate and respond to industry trends and customer requirements; (xiii) changes in the current and future markets in which Rockley is or may be engaged; (xiv) competitive and intellectual property risks; (xv) market opportunities and demand for Rockley’s products and technology, and customer products into which Rockley’s products and technology are integrated; (xvi) risks relating to international operations; (xvii) cybersecurity, privacy and infrastructure risks; (xviii) risks relating to financial and accounting matters; (xix) general economic, financial, political and business conditions, both domestic and foreign; and (xx) Rockley’s ability to realize the anticipated benefits of strategic partnerships, as well as other factors described under “Risk Factors” in Rockley’s Annual Report on Form 10-K for the fiscal year ended December 2021, and in others documents Rockley’s filings with the Securities and Exchange Commission going forward.

The forward-looking statements contained in this press release are based on various assumptions, whether or not identified in this press release, and on Rockley’s current expectations, beliefs and assumptions and are not predictions of actual performance. Should any of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results could differ materially from those discussed or implied by such forward-looking statements. There can be no assurance that future developments affecting Rockley will be those anticipated. These forward-looking statements speak only as of the date hereof, and Rockley does not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except if required by law.